MAPT and Alzheimer disease: Nevertheless, at this point we cannot rule out the possibility that additional differences in the composition of the AD brains used in this experiment (e.g., differential inflammatory response, variable Aβ40/Aβ42 ratios as suggested in Fig. 1, composition and distribution of tau pathology, etc.)are responsible for the differences in in vivo seeding.